Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardio3 appoints Atta Behfar

This article was originally published in Clinica

Executive Summary

Atta Behfar has joined Belgian biotech company Cardio3 as director for advanced research. Dr Behfar was one of the scientists involved in developing the firm's C-Cure stem cell-based therapy, and is a researcher at the Mayo Clinic in Rochester, Minnesota. In his new role, he will spend a year on assignment from the clinic to "develop and strengthen" Cardio3's research pipeline. He won the young investigator award at this year's American College of Cardiology meeting, held in March in Atlanta, Georgia, for his work on C-Cure. Mont-Saint-Guibert-based Cardio3 recently presented promising early data from the first human trial of the product, which is designed to heal damaged heart tissue by reprogramming the patient's own stem cells so that they become heart cells (, 30 June 2010).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts